Biofidelity has announced the successful completion of a study to detect key lung cancer mutations in collaboration with Agilent Technologies, a global leader in life sciences, diagnostics and applied chemicals.
The investment will fund the expansion of OrganOx’s first product, the Metra, in the US, building on commercial traction in Europe, Canada and Australia.
Ian started his career developing novel diagnostics at Celltech and has held further posts developing diagnostics at Amersham International, Abbott Laboratories and GlaxoSmithKline, before becoming CEO of Axis-Shield. During his tenure he managed the sale of the business to Alere in 2011 for £250m.
The LaingBuisson Awards, often referred to as ‘the Oscars for Healthcare’, recognise and celebrate industry excellence in the UK health and social care services.
OTIF portfolio company Sphere Fluidics has been awarded the 2019 IChemE Biotechnology award for its role in a collaborative project optimising the discovery and development of cost-effective next generation biotherapeutics with Lonza Biologics, UCB Celltech, Horizon Discovery, Alcyomics Ltd and CPI.